Navigation Links
Gerresheimer has Passed the Turning Point

DUSSELDORF, Germany, October 15 /PRNewswire-FirstCall/ --

- Nine-Month Sales (Excluding Technical Plastics) 1.7% Down on Prior Year

- EBITDA Margin at High Level of 17.2%

- As Expected, Third Quarter Marked by Inventory Reductions by Large Customers

In the first nine months of the financial year (December 2008 - August 2009), Gerresheimer AG achieved sales of EUR 744.3m (prior year EUR 783.4m). Excluding the Technical Plastics business which has been sold, sales totaled EUR 714.9m, a reduction of 1.7% compared with the prior year. The corresponding operating margin (adjusted EBITDA) for the first three quarters continued on a high level at 17.9%. In Gerresheimer's key market of pharmaceutics, long-term demand is stable although some pharma customers have continued to reduce their inventory levels. The cosmetics sales which accounts for only 10% of total Group sales remained weak as expected. For the fourth quarter, Gerresheimer expects an increase in demand for pharma packaging and a slight recovery in the cosmetics business. It has accordingly quantified more precisely the outlook for the full financial year 2009. Organic growth in the fourth quarter will be offset by the weak dollar exchange rate. For the full year a small sales decline of between 1.5% and 2.5% and an operating margin (adjusted EBITDA) of around 18.5% are expected.

"The trend in the pharma business continues to be characterized by long-term growth. We are successfully pushing ahead with the consistent orientation of the Gerresheimer Group as a leading global partner for the pharma industry," says Dr. Axel Herberg, CEO of Gerresheimer AG. "Our latest investments - particularly in the growth market of pharma plastics - reflect this."

The importance of the Plastic Systems Division, which grew by over 5% at constant exchange rates during the first three quarters, is also shown by the two recent investments. In September 2009 Gerresheimer opened a new Research and Development Center for Medical Plastic Systems in the USA and a new Production Center for Plastic Packaging in Spain.

Group sales for the third quarter were as expected down on the prior year level of EUR 268.0m at EUR 242.6m. Excluding Technical Plastics, sales totaled EUR 236.9m, a decline of 5.3% against the prior year level. In the generally stable pharma segment some customers used the summer months to carry out further inventory reductions. In the cosmetics and life science segments, sales fell substantially because of weak demand. Operationally, Gerresheimer performed well in the third quarter. Adjusted EBITDA excluding Technical Plastics came to EUR 41.6m. Thanks to capacity and cost adjustments it was possible to hold the operating margin at the high level of 17.6%.

Outlook: the turning point has been passed

Thanks to rising demand and falling inventories, slight growth is expected for the pharma business in the fourth quarter. In the cosmetics business a slight improvement in demand is also evident, while in the Life Science Research segment no real recovery is foreseeable. For the financial year 2009, Gerresheimer has quantified more precisely the outlook last given in July 2009. For the full financial year the company assumes a slight sales decline of 1.5% to 2.5% and an operating margin (adjusted EBITDA) of around 18.5%. For the full financial year 2009 a total investment volume of around EUR 85 - 90m is expected.

"Thanks to our pharma orientation and very early capacity adjustments and cost reduction measures, our business is stable. We see indications that the turning point has already been passed in the third quarter," Herberg says.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR 1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

    Group Key Figures
    (IFRS; End of Q3: August 31; Financial Year end November 30)

    in EUR million           Q3      Q3  Change  Q1-Q3 Q1-Q3 Change  FY 2008
                            2009    2008      %   2009  2008      %

    Net sales              242.6   268.0   -9.5  744.3 783.4   -5.0  1.060.1

    Group net sales
     excluding Technical
     Plastics[1]           236.9   250.2   -5.3  714.9 727.4   -1.7    985.9
    Adjusted EBITDA[2]      42.0    50.3  -16.5  127.8 146.9  -13.0    206.4
    in % of net sales       17.3    18.8          17.2  18.8            19.5
    Adjusted EBITDA[2]
     excluding Technical
     Plastics               41.6    N/A[3]       128.1   N/A[3]        N/A[3]
    in % of net sales       17.6    N/A[3]        17.9   N/A[3]        N/A[3]

    Profit from
     operations (EBIT)      12.9   -10.9          33.9  22.5  +50.7     61.0
    Net income              -4.0   -22.8          -4.2 -14.7             4.5
    Adjusted net income[4]   7.9    16.5  -52.1   28.6  44.0  -35.0     61.4
    Earnings per share
     in EUR                 -0.11   -0.73         -0.15 -0.53            0.02
    Adjusted earnings        0.20    0.52 -61.5    0.83  1.34 -38.1      1.83
     per share[5] in EUR


    1 Net sales of the recently divested Technical Plastics business (sold
      with effect from July 1, 2009) include the sales of the Technical
      Plastics tool business and amounted to EUR 74.2m in FY 2008

    2 Adjusted EBITDA: Earnings before income taxes, financial result,
      amortization of fair value adjustments, extraordinary depreciation,
      depreciation and amortization, restructuring expenses and one-off
      income and expenses

    3 The adjusted EBITDA of the Technical Plastics business of the
      comparative prior year period is not available due to the fact that the
      divestment was carried out in the course of the financial year and is
      therefore included in the Plastic Systems segment

    4 Adjusted net income: Consolidated profit before non-cash amortization
      of fair value adjustments, special effects from restructuring expenses,
      extraordinary depreciation, the balance of one-off income and expenses
      (including significant non-cash expenses) and the related tax effects

    5 Adjusted net income after minorities divided by 31.4m shares


    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121

SOURCE Gerresheimer AG

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Scientists Reveal Roadmap to Brain Health That Can Be Passed Down to Future Generations: Exercise, Omega-3, Folic Acid, Vitamin B6, and Vitamin B12
2. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
6. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
7. AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
10. West Pharmaceutical Services, Inc. Appoints New Director
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Asia Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise ... the Demand " report to their offering. ... --> Boston scientific and others. ... players including Medtronic, Biotronik, Boston scientific ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... of Toronto and the University of British Columbia suggested that laws requiring bicyclists to ... article explains that part of the reason for the controversial conclusion is that, while ...
(Date:11/27/2015)... ... ... The rapid speed at which Americans are aging is ... needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. Health ... of this equation: 80 percent of medical care occurs in the home, by ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... Orange County, CA (PRWEB) , ... November 27, 2015 , ... ... holiday season , The company is offering customers 10% off of their purchase of ... purchase any treatment at full price. According to a company spokesperson. “Finding lice is ...
Breaking Medicine News(10 mins):